Terry Heiman-Patterson, MD, Director of the Temple MDA/ALS Center of Hope, offered insight to Neurology Today about the news that the 48-week randomized, placebo-controlled phase 3 PHOENIX trial on Relyvrio did not meet its primary and secondary endpoints. The clinical trial had enrolled 664 adults with amyotrophic lateral sclerosis, or ALS.
IMPORTANT: As of 8:00 AM on September 3, Temple University Hospital – Main Campus (Broad and Ontario Streets) will no longer provide Labor and Delivery services. All childbirth services will be relocated to our new hospital location.
TRANSIT ALERT: Major cuts to bus, subway, and rail may affect travel to and from our campuses. Read full update.
800-TEMPLE-MED
Schedule Appointment
SEARCH TEMPLE HEALTH